Andere talen Livzon Pharmaceutical Group Inc.

Aandelen

000513

CNE0000002Y8

slotkoers Shenzhen S.E. Andere beurzen 00:00:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
38,15 ^CNY	+2,42%		+0,93%	+8,97%

24/04	Livzon Pharmaceutical's Q1-winst stijgt met 4,5%; omzet daalt met 5%	MT
23/04	Livzon Pharmaceutical Group Inc. Rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Livzon Pharmaceutical's Q1 Profit Jumps 4.5%; Revenue Slips 5%	24/04
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	23/04
Tranche Update on Livzon Pharmaceutical Group Inc.'s Equity Buyback Plan announced on January 19, 2024.	02/04
Livzon Pharma's 2023 Profit Rises 2%; Revenue Falls 2%	29/03
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024	28/03
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug	23/02
Livzon Group Livzon Medical Research Centre Receives Notice of Drug Clinical Trial Approval Issued by China National Medical Products Administration	22/02
Livzon Pharma Gets Nod to Trial Weight Management Drug	06/02
Livzon Pharmaceutical Appoints Former Joincare Exec as Vice President	30/01
Livzon Pharmaceutical Group Inc. commences an Equity Buyback Plan for CNY 600 million worth of its shares, under the authorization approved on Decemeber 19, 2023.	18/01
Livzon Pharma Recognizes Credit, Asset Impairments	10/01
Livzon Pharmaceutical to Continue Getting Services from Joincare Pharmaceutical	02/01
Livzon Pharmaceutical Shareholders to Vote on Spin-Off, Separate Listing of Livzon Diagnostics	19/12
Livzon Pharma's 190 Products Added to China's National Reimbursement Drug List	14/12
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use	04/12
Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use	03/12
Livzon Pharmaceutical Group Inc. completed the acquisition of an additional 5% stake in Zhuhai Livzon Diagnostics Inc. from Shi Jianfeng.	21/11
Livzon Pharmaceutical Group Inc. completed the acquisition of an additional 3% stake in Zhuhai Livzon Diagnostics Inc. from Li Lin.	21/11
Livzon Pharma Boosts Stake in Diagnostic Equipment Unit Ahead of Spinoff	20/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Livzon Pharmaceutical Group Inc.

Aandelen

000513

CNE0000002Y8

Andere talen

Filters